Drug Profile


Alternative Names: Affinitac; Affinitak; Aprenocarsen sodium; CGP 64128A; ISIS 3521; LY 900003

Latest Information Update: 04 Mar 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Colorectal cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 04 Mar 2005 Discontinued - Phase-II for Brain cancer in Canada (IV-infusion)
  • 04 Mar 2005 Discontinued - Phase-II for Brain cancer in Europe (IV-infusion)
  • 04 Mar 2005 Discontinued - Phase-II for Brain cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top